Biotechnology company Adicet Bio Inc (NASDAQ: ACET) announced on Monday that it has opened enrollment for a Phase 1 clinical trial evaluating ADI-001 in autoimmune diseases, including lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and ANCA-associated vasculitis (AAV).

The trial, which will assess safety and tolerability, has activated clinical sites for LN patients, with enrollment for SLE, SSc and AAV expected in Q4 2024.

ADI-001, an allogeneic gamma delta CAR T cell therapy targeting B-cells via an anti-CD20 CAR, recently received FDA Fast Track Designation for relapsed/refractory class III or IV LN.

The trial's secondary objectives will focus on cellular kinetics, pharmacodynamics and disease activity.